Clinical Trial Update: Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating concomitant administration of Prevnar 13 with an influenza vaccine in adults previously vaccinated with Pneumovax 23. The study address…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease

Drugs mentioned

• Influenza vaccine (influenza vaccine)
• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE | Phase 4 | Status: COMPLETED | Results posted: 2016-07-01